RSRobyn T. Sussman

Robyn T. Sussman

*This is an algorithmically generated author record based on publicly available information.

Robyn T. Sussman has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors

    by Daniel Ackerman, Elisabeth R Seyferth, Wuyan Li, Julia E Youngman, Jelsia N Cottone, Cecilia A Wright, Robyn T Sussman, Abashai A Woodard, David C Metz, Bryson W Katona, et al.

    Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies, including optical genome mapping (OGM) and whole exome sequencing (WES), to 70 liver metastases of NETs from multiple anatomical primary sites to identify actionable genomic alterations. We detected recurrent fusions involving TBL1X (PSIP1::TBL1X) and BEND2 (CHD7::BEND2 and NEO1::BEND2) by OGM in pancreatic neuroendocrine tumors (pNETs). The expression of the PSIP1::TBL1X fusion was confirmed by PacBio Iso-Seq long-read transcriptome sequencing and nested rtPCR, and fusion protein expression was established by western blotting. Expression of the PSIP1::TBL1X fusion was also assayed in a separate cohort of 31 specimens from 28 pNET cases by rtPCR. Across both cohorts, PSIP1::TBL1X was identified in 11% of pNET patients with available metastatic tissue, but was not detected in primary tumor specimens. All PSIP1::TBL1X fusion isoforms were found to retain early exons of PSIP1 and the complete coding sequence of TBL1X. Consistent with prior reports, BEND2 fusions were associated with high-grade tumors and may represent a clinically useful biomarker for aggressive disease. Notably, TBL1X and BEND2 fusions did not co-occur with ATRX/DAXX mutations, defining a distinct molecular subgroup of pNETs. This study highlights the importance of structural variant profiling in molecular profiling studies and supports a revised view of the role of gene fusions in neuroendocrine malignancies.

  • Open Access

    Optical genome mapping identifies a novel PSIP1::TBL1X fusion in metastatic pancreatic neuroendocrine tumors

    by Daniel Ackerman, Elisabeth R. Seyferth, Wuyan Li, Julia E. Youngman, Jelsia N. Cottone, Cecilia A. Wright, Robyn T. Sussman, Abashai A. Woodard, David C. Metz, Bryson W. Katona, et al.

    Background and aims Effective treatment of metastatic neuroendocrine tumors is limited by a lack of targeted therapies and clinically useful predictive biomarkers. We applied complementary genomic profiling technologies to identify genomic alterations that could lead to actionable drug targets and biomarkers. Methods Optical genome mapping (OGM) and whole exome sequencing (WES) was performed on 70 liver metastases of neuroendocrine tumors from multiple anatomical primary sites. PacBio IsoSeq long read sequencing and western blotting was used to confirm fusion gene expression. Findings were validated by rtPCR and western blotting on a separate cohort of 17 resection specimens from 14 pNET cases. Results Somatic variant calling from OGM data detected recurrent fusions involving TBL1X ( PSIP1::TBL1X ) and BEND2 ( CHD7::BEND2 and NEO1::BEND2 ) in pancreatic neuroendocrine tumors (pNETs). BEND2 fusions were associated with high grade tumors, as previously described. The novel PSIP1::TBL1X fusion was confirmed to result in fusion transcript expression by both long-read sequencing and nested rtPCR. Presence of the PSIP1::TBL1X fusion transcript was also confirmed in a second cohort of pNET resection specimens and fusion protein expression was established by western blotting. Both TBL1X and BEND2 fusions are mutually exclusive with ATRX/DAXX mutations. Conclusion This study underscores the importance of structural variants, including fusion genes as both prognostic biomarkers and potential therapeutic targets, especially in ATRX/DAXX negative pNETs. BEND2 fusion positivity may be a clinically useful biomarker for aggressive disease. As all TBL1X fusion isoforms contain the entire TBL1X coding sequence, TBL1X inhibition could be explored as a novel treatment for TBL1X fusion positive pNETs.

  • Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis

    by Jacob E. Till, Taylor A. Black, Caren Gentile, Aseel Abdalla, Zhuoyang Wang, Hareena K. Sangha, Jacquelyn J. Roth, Robyn Sussman, Stephanie S. Yee, Mark H. O'HAra, et al.


  • Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML

    by Robyn T. Sussman, Bryan Manning, Daniel Ackerman, Ashkan Bigdeli, Paige Pammer, Priya D. Velu, Selina M. Luger, Adam Bagg, Martin Carroll, Jennifer J.D. Morrissette


  • Open Access

    Epigenomic profiling of neuroblastoma cell lines

    by Kristen Upton, Apexa Modi, Khushbu Patel, Karina L. Conkrite, Robyn T. Sussman, Gregory P. Way, Rebecca N. Adams, Gregory I. Sacks, Paolo Fortina, Sharon J. Diskin, et al.

    Understanding the aberrant transcriptional landscape of neuroblastoma is necessary to provide insight to the underlying influences of the initiation, progression and persistence of this developmental cancer. Here, we present chromatin immunoprecipitation sequencing (ChIP-Seq) data for the oncogenic transcription factors, MYCN and MYC, as well as regulatory histone marks H3K4me1, H3K4me3, H3K27Ac, and H3K27me3 in ten commonly used human neuroblastoma-derived cell line models. In addition, for all of the profiled cell lines we provide ATAC-Seq as a measure of open chromatin. We validate specificity of global MYCN occupancy in MYCN amplified cell lines and functional redundancy of MYC occupancy in MYCN non-amplified cell lines. Finally, we show with H3K27Ac ChIP-Seq that these cell lines retain expression of key neuroblastoma super-enhancers (SE). We anticipate this dataset, coupled with available transcriptomic profiling on the same cell lines, will enable the discovery of novel gene regulatory mechanisms in neuroblastoma.


  • Top Cited Papers

    Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma

    by Kristopher R. Bosse, Pichai Raman, Zhongyu Zhu, Maria Lane, Daniel Martinez, Sabine Heitzeneder, Komal S. Rathi, Nathan M. Kendsersky, Michael Randall, Laura Donovan, et al.


  • Delayed Accumulation of H3K27me3 on Nascent DNA Is Essential for Recruitment of Transcription Factors at Early Stages of Stem Cell Differentiation

    by Svetlana Petruk, Jingli Cai, Robyn Sussman, Guizhi Sun, Sina K. Kovermann, Samanta A. Mariani, Bruno Calabretta, Steven B. McMahon, Hugh W. Brock, Lorraine Iacovitti, et al.


  • Open Access

    Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes

    by Yang Feng, Yanping Wang, Zhongyu Zhu, Wei Li, Robyn T. Sussman, Michael Randall, Kristopher R. Bosse, John M. Maris, Dimiter S. Dimitrov

    CD56 (NCAM, neural cell adhesion molecule) is over-expressed in many tumor types, including neuroblastoma, multiple myeloma, small cell lung cancer, ovarian cancer, acute myeloid leukemia, NK-T lymphoma, neuroendocrine cancer and pancreatic cancer. Using phage display, we identified 2 high-affinity anti-CD56 human monoclonal antibodies (mAbs), m900 and m906, which bound to spatially separated non-overlapping epitopes with similar affinity (equilibrium dissociation constant 2.9 and 4.5 nM, respectively). m900 bound to the membrane proximal fibronectin type III-like domains, whereas m906 bound to the N-terminal IgG-like domains. m906 induced significant down-regulation of CD56 in 4 neuroblastoma cell lines tested, while m900-induced downregulation of CD56 was much lower. Antibody-drug conjugates (ADCs) made by conjugation with a highly potent pyrrolobenzodiazepine dimer (PBD) exhibited killing activity that correlated with CD56 down-regulation, and to some extent with in vivo binding ability of the antibodies. The m906PBD ADC was much more potent than m900PBD, likely due to higher CD56-mediated downregulation and stronger binding to cells. Treatment with m906PBD ADC resulted in very potent cytotoxicity (IC50: 0.05–1.7 pM). These results suggest a novel approach for targeting CD56-expressing neuroblastoma cells. Further studies in animal models and in humans are needed to find whether these antibodies and their drug conjugates are promising candidate therapeutics.


  • Top Cited Papers

    Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

    by Elena Sotillo, David M. Barrett, Kathryn L. Black, Asen Bagashev, Derek Oldridge, Glendon Wu, Robyn Sussman, Claudia Lanauze, Marco Ruella, Matthew R. Gazzara, et al.

    The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor–armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous deletions spanning the CD19 locus and de novo frameshift and missense mutations in exon 2 of CD19 in some relapse samples. However, we also discovered alternatively spliced CD19 mRNA species, including one lacking exon 2. Pull-down/siRNA experiments identified SRSF3 as a splicing factor involved in exon 2 retention, and its levels were lower in relapsed B-ALL. Using genome editing, we demonstrated that exon 2 skipping bypasses exon 2 mutations in B-ALL cells and allows expression of the N-terminally truncated CD19 variant, which fails to trigger killing by CART-19 but partly rescues defects associated with CD19 loss. Thus, this mechanism of resistance is based on a combination of deleterious mutations and ensuing selection for alternatively spliced RNA isoforms. Significance: CART-19 yield 70% response rates in patients with B-ALL, but also produce escape variants. We discovered that the underlying mechanism is the selection for preexisting alternatively spliced CD19 isoforms with the compromised CART-19 epitope. This mechanism suggests a possibility of targeting alternative CD19 ectodomains, which could improve survival of patients with B-cell neoplasms. Cancer Discov; 5(12); 1282–95. ©2015 AACR. See related commentary by Jackson and Brentjens, p. 1238. This article is highlighted in the In This Issue feature, p. 1225